PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34548332-7	2022	We further developed a preclinical strategy to enhance the efficacy of HER3-DXd through osimertinib pre-treatment, which increased membrane expression of HER3 and led to enhanced internalization and efficacy of HER3-DXd.	osimertinib	88-99	erb-b2 receptor tyrosine kinase 3	Homo sapiens	71-75	
34548332-7	2022	We further developed a preclinical strategy to enhance the efficacy of HER3-DXd through osimertinib pre-treatment, which increased membrane expression of HER3 and led to enhanced internalization and efficacy of HER3-DXd.	osimertinib	88-99	erb-b2 receptor tyrosine kinase 3	Homo sapiens	154-158	
34548332-7	2022	We further developed a preclinical strategy to enhance the efficacy of HER3-DXd through osimertinib pre-treatment, which increased membrane expression of HER3 and led to enhanced internalization and efficacy of HER3-DXd.	osimertinib	88-99	erb-b2 receptor tyrosine kinase 3	Homo sapiens	211-215	
34077739-8	2021	In osimertinib resistant H1975 cells, the drug combination was less capable of inactivating AKT, mTOR, STAT3, STAT5, ERK1/2 whereas it gained the ability to inactivate ERBB3.	osimertinib	3-14	erb-b2 receptor tyrosine kinase 3	Homo sapiens	168-173	
35347108-5	2022	Osimertinib led to apoptosis of tumors but simultaneously, it triggered inositol-requiring-enzyme (IRE1alpha)-dependent HER3 upregulation, increased macrophage infiltration, and activated cGAS in cancer cells to produce cGAMP (detected by a lentivirally transduced STING activity biosensor), transactivating STING in macrophages.	osimertinib	0-11	erb-b2 receptor tyrosine kinase 3	Homo sapiens	120-124	
35347108-6	2022	We sought to target osimertinib-induced HER3 upregulation with monoclonal antibodies, which engaged Fc receptor-dependent tumor elimination by macrophages, and STING agonists enhanced macrophage-mediated tumor elimination further.	osimertinib	20-31	erb-b2 receptor tyrosine kinase 3	Homo sapiens	40-44